Published: August 8, 2019

Introduction {#sec1}
============

Pathogenic viruses have evolved a diverse array of mechanisms to avoid or impair the host innate immune antiviral response ([@bib66]), particularly by evading those pathways that result in type I interferon (IFN) production and signaling ([@bib24]). For example, Ebola virus (EBOV) relies on its structural protein VP35 to inhibit viral double-stranded RNA (dsRNA) sensing by retinoic-acid-inducible protein I (RIG-I) ([@bib8], [@bib34], [@bib38]) and the IFN-inducible double-stranded (ds)RNA sensor protein kinase R (PKR) ([@bib21], [@bib59]), thus avoiding the triggering and amplification of the host type I IFN response. The critical role played by VP35 in productive EBOV infection was underscored by the finding that mutations introduced into VP35 that disrupted its ability to sequester viral RNA intermediates, which did not affect its function in EBOV replication, resulted in increased type I IFN induction *in vitro* and severely attenuated viral growth *in vivo* in mice ([@bib27]) and guinea pigs ([@bib49]). A host-directed therapy that could overcome this potent VP35-dependent EBOV immune evasion strategy would thus be particularly useful.

Nitazoxanide (NTZ) is an oral US Food and Drug Administration (FDA)-approved drug that has been used in millions of adults and children since 2004 with minimal adverse side effects for the treatment of *Giardia*- and *Cryptosporidium*-associated diarrhea, including in patients co-infected with HIV ([@bib18], [@bib29], [@bib53]). NTZ and its circulating metabolite tizoxanide (TIZ) have also been reported to inhibit a diverse array of viruses in tissue culture and in small animal models ([@bib51]). In humans, NTZ reduces symptom duration of uncomplicated influenza ([@bib26]), viral gastroenteritis ([@bib52]), and rotaviral diarrhea ([@bib54]). Several mechanisms have been proposed to contribute to NTZ\'s activity against specific viruses ([@bib3], [@bib23], [@bib36], [@bib47], [@bib57], [@bib60]), including studies showing enhancement or induction of IFN-stimulated gene (ISG) expression by NTZ ([@bib25], [@bib45], [@bib65]) and studies showing a weak association between NTZ and PKR activation ([@bib3], [@bib19]). However, no functional link between NTZ\'s antiviral activity and any specific ISG or with PKR has been demonstrated, and the molecular mechanisms underlying its broad-spectrum antiviral effects on host cells remain unknown.

Here, we show that treatment of cells with NTZ results in broad amplification of the host innate immune response, including an increase in RIG-I-like receptor (RLR) activation in response to stimulation with cytoplasmic dsRNA, enhanced mitochondrial antiviral signaling protein (MAVS) and interferon regulatory factor 3 (IRF3) activities, and transcriptional induction of the antiviral phosphatase GADD34. Based on these data, we hypothesized that NTZ could limit or overcome EBOV\'s ability to evade detection by critical innate immune sensors following viral entry. At concentrations reflective of routine oral dosing for parasitic infections, NTZ significantly inhibits EBOV replication in A549 cells. Furthermore, using CRISPR/dead (d)Cas9-KRAB promoter targeting to ablate expression of individual host factors, we show that NTZ\'s inhibitory effect against EBOV relies on both RIG-I and PKR, indicating that NTZ can overcome EBOV VP35\'s ability to prevent viral detection by these cytoplasmic sensors. We also show that NTZ significantly inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through a distinct mechanism involving both RIG-I and GADD34, but not PKR, consistent with the different innate immune evasion strategies employed by VSV when compared with EBOV. Thus, NTZ establishes a broad "antiviral" milieu that is rapidly amplified upon viral infection and is capable of counteracting varied virus-specific immune evasion strategies, such as those employed by EBOV and VSV.

With no effective and easily deployable oral drug to treat or prevent infection, EBOV caused over 10,000 deaths in the 2014--2016 west African EBOV epidemic ([@bib62]) and has claimed over 1,700 lives to date (as of July 21, 2019) in the current outbreak in the Democratic Republic of the Congo ([@bib10], [@bib68]). Our demonstration that NTZ significantly inhibits EBOV replication *in vitro* suggests that NTZ could have a potential role in the treatment of acute EBOV disease, prevention of EBOV infection in exposed healthy individuals, and eradication of EBOV reservoirs that persist in immune-privileged sites of patients who have been cured of EBOV disease ([@bib17]), and it provides impetus to test NTZ in animal models of EBOV infection to demonstrate *in vivo* efficacy.

Results {#sec2}
=======

To test whether NTZ enhances sensing by the RLR pathway, we overexpressed full-length RIG-I or melanoma differentiation-associated protein 5 (MDA5), the two major RLR proteins, in human embryonic kidney (HEK) 293T cells that were co-transfected with an IFN-β promoter-driven luciferase reporter plasmid (IFN-β LUC). We then examined whether NTZ augmented IFN-β promoter activity in the presence or absence of a viral nucleic acid analog, the synthetic dsRNA poly I:C. NTZ pretreatment enhanced poly I:C-stimulated IFN-β promoter activity in RIG-I- ([Figure 1](#fig1){ref-type="fig"}A, left) and in MDA5- ([Figure 1](#fig1){ref-type="fig"}A, right) overexpressing cells in a dose-dependent manner ([Figure 1](#fig1){ref-type="fig"}A). In the case of MDA5 overexpression, NTZ\'s effect on IFN-β reporter gene activity was evident even in the absence of poly I:C treatment ([Figure 1](#fig1){ref-type="fig"}A, right).Figure 1NTZ Broadly Enhances the IFN Pathway(A) IFN-β reporter activity in HEK293T cells co-transfected with RIG-I (left panel) or MDA5 (right panel) expression vectors or empty vector control with increasing amounts of NTZ in the presence and absence of poly I:C. Values were normalized against IFN-β reporter activity with empty vector in the absence of NTZ and poly I:C. Error bars represent standard deviations.(B) IFN-β reporter activity in HEK293T cells co-transfected with a RIG-I expression vector or empty vector control with increasing amount of NTZ in the presence and absence of 42bp 5′ppp dsRNA (1AB) (left panel). Values were normalized against the IFN-β reporter activity with empty vector in the absence of NTZ and 1AB. Relative expression of IFN-β mRNA in HEK293T cells stimulated with 1AB or mock in the presence or absence of NTZ (right panel). Values were calculated relative to the housekeeping gene GAPDH and normalized against mock 1AB-transfected HEK293T cells without NTZ (DMSO). Error bars represent standard deviations.(C) IFN-β reporter activity in HEK293T cells co-transfected with MAVS or empty vector control with increasing amounts of NTZ. Values were normalized against the reporter activity with empty vector in the absence of NTZ. Error bars represent standard deviations.(D) IFN-β reporter activity in HEK293T cells co-transfected with different concentrations of a phosphomimetic IRF3 (IRF3-5D) or empty vector control with increasing amount of NTZ. Values were normalized against the reporter activity with empty vector in the absence of NTZ. Error bars represent standard deviations.(E) Relative expression of Mx1, IFI27, and IFITM3 mRNA in HEK293T cells treated with human recombinant IFN-β and increasing concentrations of NTZ. Values were calculated relative to the housekeeping gene GAPDH and normalized against no IFN-β treatment in the absence of NTZ. Error bars represent standard deviations.

RIG-I and MDA5 differentially recognize distinct viral RNA signatures ([@bib30]). RIG-I preferentially recognizes 5′ triphosphosphorylated short dsRNA structures typically generated by negative-strand RNA viruses, whereas MDA5 recognizes longer dsRNA structures ([@bib31], [@bib58]). To more precisely distinguish NTZ\'s effects on these RNA sensors, we next tested the effect of NTZ on a more specific RIG-I stimulus by using a short (42 bp) 5′ phosphorylated synthetic dsRNA (1AB) ([@bib44]). We found that IFN-β reporter activity was also significantly enhanced by NTZ in the RIG-I-overexpressing cells that were stimulated with 1AB ([Figure 1](#fig1){ref-type="fig"}B, left panel). Furthermore, endogenous IFN-β mRNA synthesis was significantly enhanced by NTZ pretreatment before 1AB stimulation of 293T cells ([Figure 1](#fig1){ref-type="fig"}B, right panel).

We next tested the ability of NTZ pretreatment to activate IFN-β reporter gene activity in HEK293T cells co-transfected with a plasmid overexpressing MAVS, the adaptor protein through which RIG-I and MDA5 signal ([@bib32], [@bib41], [@bib61], [@bib70]). IFN-β LUC activity was strongly enhanced by NTZ in MAVS-overexpressing cells even in the absence of any other cellular stimulation, reaching a \>4-fold increase at a concentration of 10 μM NTZ ([Figure 1](#fig1){ref-type="fig"}C).

It has been reported that in addition to preventing IRF3 phosphorylation and activation by blocking RIG-I viral RNA sensing, EBOV VP35 also prevents IRF3 phosphorylation by directly blocking the access of the kinases IKKε and TBK-1 to unphosphorylated IRF3 ([@bib48]). To determine if NTZ can directly augment IRF3\'s activity, we next transfected HEK293T cells with a plasmid encoding phosphomimetic IRF3, which is able to drive IFN-β mRNA expression in the absence of proximal components of the RLR signaling pathway ([@bib37]). As shown in [Figure 1](#fig1){ref-type="fig"}D, NTZ enhanced IRF3-induced IFN-β reporter activity in a dose-dependent manner. Furthermore, we also found that NTZ enhanced type I IFN-induced transcription of the ISGs Mx1, IFI27, and IFITM3 ([Figure 1](#fig1){ref-type="fig"}E). Thus, NTZ broadly enhances signaling downstream of the RLR and IFN-β signaling pathways in addition to acting as an agonist for viral RNA sensors acting at the proximal part of the pathway in the cytoplasm.

Physiological NTZ Concentrations Strongly Restrict EBOV Replication {#sec2.1}
-------------------------------------------------------------------

Our data that NTZ broadly enhances antiviral sensing via the cytoplasmic RLR pathway and amplifies type I IFN-induced gene expression, including IFITM3 gene synthesis, which has previously been shown to inhibit EBOV infection ([@bib28]), led us to speculate that NTZ may overcome EBOV\'s capacity to evade host RNA sensing and to skirt triggering of the type I IFN response ([@bib5], [@bib6], [@bib8], [@bib27], [@bib34], [@bib38]), thus favoring host control of the virus. To test this hypothesis, we examined the ability of NTZ to inhibit infectious EBOV growth in human pulmonary epithelial A549 cells *in vitro* under biosafety level 4 conditions using an isolate of infectious EBOV from the original 1995 outbreak in the Democratic Republic of the Congo (Kikwit). Cells were pretreated with 0, 20, or 40 μM NTZ, which is not toxic to A549 cells (see [Figure 3](#fig3){ref-type="fig"}A), for 4 h, and were then infected with EBOV at an MOI of 0.01. As shown in [Figure 2](#fig2){ref-type="fig"}, in vehicle-only treated cells, EBOV growth increased by over 1.5 log units by 72 h post-infection. By contrast, over the same time frame, EBOV growth was completely inhibited in cells treated with 20 or 40 μM of NTZ (p \< 0.001), dropping 2.5 log units from the initial inoculum titer in the cells treated with 40 μM NTZ (p \< 0.001). We note that 20 and 40 μM are concentrations of NTZ that are either well below or equivalent to peak plasma levels (∼39 μM) of its active metabolite TIZ that are observed in humans who have ingested 500 mg of NTZ twice a day in a typical oral regimen for cryptosporidial diarrhea ([@bib50]).Figure 2NTZ Inhibits EBOV Infection/Replication in A549 CellsA549 cells were mock-treated or treated with 20 or 40 μM NTZ for 4 h and infected with EBOV-Kikwit at MOI of 0.01 in the presence of the cellular supernatants from the NTZ-pretreated cells. Supernatants were harvested at 1, 48, or 72 h post-infection, clarified, and EBOV plaque-forming unit (PFU) was calculated by plaque assay. Results shown as PFU/mL (A) and log~10~ PFU/mL (B). \*\*\*p \< 0.001. When NTZ was added 24 h before Ebola infection it similarly inhibited viral growth.

NTZ Inhibits VSV Replication through RIG-I but Not PKR {#sec2.2}
------------------------------------------------------

To begin to characterize the mechanisms involved in NTZ\'s antiviral activity, we next tested NTZ\'s effect on a second RNA virus, the rhabdovirus VSV, which, like EBOV, is a member of the order Mononegavirales, and which also allowed testing under biosafety level 2 conditions. NTZ pretreatment of A549 cells for 4 h inhibited the growth of a firefly luciferase-expressing VSV (VSV-Luc) reporter virus ([@bib15]) in A549 cells, with greater than 99% inhibition of VSV-Luc achieved at an NTZ concentration of 12 μM and \>99.9% inhibition obtained at 18 μM ([Figure 3](#fig3){ref-type="fig"}A, left).Figure 3NTZ Strongly Inhibits VSV Infection/Replication in A549 Cells: Depletion of RIG-I and GADD34, but Not PKR, Impairs Anti-VSV Activity of NTZ(A) Left panel: A549 cells were treated with NTZ at the indicated concentrations for 4 h and were then infected with a VSV firefly luciferase reporter ([@bib15]). After 16 h, cells were harvested and firefly luciferase activity was measured by luminescence assay. Means and standard deviations from three independent experiments performed in duplicate are shown. Right panel: A549 cells were treated with vehicle or NTZ at the indicated concentrations for 18 h. Cells were harvested, exposed to 1 μM propidium iodide for 5 min, and subjected to flow cytometry.(B) Protein expression levels were efficiently knocked down in A549 cells by CRISPR/dCas9-KRAB in combination with guide RNA (gRNA) targeting the promoters of the RIG-I, PKR, or GADD34 genes, respectively. Protein expression levels of RIG-I, PKR, and GADD34 were evaluated by western blot analysis. For GADD34, cells were stimulated by vehicle control DMSO (−) at 0.1%, tunicamycin (TN) at 10 μg/mL or nitazoxanide (NTZ) at 25 μM for 8 h.(C) Left panel: lentiviral targeting of dCas9-KRAB to the RIG-I gene promoter in A549 cells inhibits RIG-I gene expression in both the absence and presence of IFN-β stimulation. Right panel: CRISPR-control or CRISPR-RIG-I A549 cells were seeded at equal density, treated with NTZ at the indicated concentrations for 4 h, infected with VSV-Luc for 16 h, and firefly luciferase activity was quantitated. Means and standard errors are shown from three independent experiments performed in duplicate. NTZ inhibitory activity is presented as firefly luciferase signal as a percentage of vehicle (DMSO) control. Forward and reverse qPCR primer pairs: Cyclophilin B, 5′-AGAAGAAGGGGCCCAAAGT-3′, 5′-AAAGATCACCCGGCCTACAT-3′; RIG-I, 5′-GAAGACCCTGGACCCTACCTA-3′, 5′-CCATTGGGCCCTTGTTGTTT-3′.(D) Left panel: lentiviral targeting of dCas9-KRAB to the PKR gene promoter in A549 cells potently inhibits PKR gene expression in both the absence and presence of IFN-β stimulation. Right panel: CRISPR-control or CRISPR-PKR A549 cells were seeded at equal density, treated with NTZ at the indicated concentrations for 4 h, infected with VSV-Luc for 16 h, and firefly luciferase activity was quantitated. Means and standard errors are shown from three independent experiments performed in duplicate. NTZ inhibitory activity is presented as firefly luciferase signal as a percentage of vehicle (DMSO) control. Forward and reverse qPCR primer pairs: Cyclophilin B as in (B); PKR, 5′-TTTGGACAAAGCTTCCAACC-3′, 5′-CTACTCCCTGCTTCTGACGG-3′.(E) A549 cells were mock-treated or treated with 10, 20, or 40 μM NTZ for 4 h and GADD34 transcript levels were measured. We note that we tested a range of time points between 1 and 8 h after 40 μM NTZ stimulation of A549 cells and found that GADD34 mRNA levels peaked between 4 and 8 h (data not shown). GADD34 transcript levels are expressed as a percentage of the housekeeping gene cyclophilin B. Mean and SD of three independent experiments are shown. \*p \< 0.05, \*\*\*p \< 0.001. Forward and reverse qPCR primer pairs: Cyclophilin B as in (B); GADD34, 5′-GGTGCCAACCCAGTGATGAA-3′, 5′-TTCAGGAAGGCACTTGGTGG-3′.(F) Left panel: lentiviral targeting of dCas9-KRAB to the GADD34 gene promoter in A549 cells strongly inhibits GADD34 gene expression in both the absence and presence of NTZ stimulation. Right panel: CRISPR-control or CRISPR-GADD34 A549 cells were seeded at equal density, treated with NTZ at the indicated concentrations for 4 h, infected with VSV-Luc for 16 h, and firefly luciferase activity was quantitated. Means and standard errors are shown from three independent experiments performed in duplicate. NTZ inhibitory activity is presented as firefly luciferase signal as a percentage of vehicle (DMSO) control. Forward and reverse qPCR primer pairs are described in (D).

Given the importance of both RIG-I and PKR in EBOV\'s evasion of the host antiviral response ([@bib8], [@bib21], [@bib34], [@bib38], [@bib59]), and reports that NTZ can weakly induce auto-phosphorylation of PKR ([@bib3], [@bib19]), we next sought to determine the role of these molecules in NTZ\'s antiviral activity using the VSV model system. Because traditional short hairpin RNA (shRNA)-based methods of gene knockdown, including in A549 cells, are associated with both non-specific type I IFN induction by the shRNA itself, and reduced shRNA activity in response to type I IFN stimulation ([@bib40]), we chose to knockdown RIG-I or PKR expression in A549 cells by targeting dead(d)Cas9-KRAB to their genes\' promoters (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} and [Figure S1](#mmc1){ref-type="supplementary-material"} for gRNA target sequences and [Figure 3](#fig3){ref-type="fig"}B for protein knockdown efficiency). RIG-I depletion ([Figure 3](#fig3){ref-type="fig"}C, left panel) led to significantly increased VSV-Luc growth ([Figure 3](#fig3){ref-type="fig"}C, right panel, see 0 μM NTZ data point) and to a strong reduction in VSV-Luc\'s sensitivity to NTZ (50% inhibition at 4.8 μM NTZ in CRISPR-Ctrl A549 cells versus 8.0 μM NTZ in CRISPR-RIG-I A549 cells) ([Figure 3](#fig3){ref-type="fig"}C, right panel). Depletion of PKR ([Figure 3](#fig3){ref-type="fig"}D, left panel) also resulted in significantly increased VSV-Luc growth ([Figure 3](#fig3){ref-type="fig"}D, right panel, 0 μM NTZ data point). However, NTZ\'s ability to block VSV replication was not impaired in PKR-depleted cells at any NTZ concentration tested (50% inhibition with 4.8 μM NTZ in CRISPR-Ctrl A549 cells versus 4.7 μM NTZ in CRISPR-PKR A549 cells) ([Figure 3](#fig3){ref-type="fig"}D, right panel), indicating that NTZ\'s suppression of VSV replication is not dependent on PKR.

NTZ Inhibition of VSV Growth Depends in Part on GADD34 {#sec2.3}
------------------------------------------------------

The phosphatase GADD34 selectively promotes IFN-β translation in the context of host global translational shutdown following PKR-dependent eIF2α phosphorylation or stress pathway activation ([@bib16]). NTZ has previously been shown to induce low levels of endoplasmic reticulum stress ([@bib3]) and to promote the translation of the transcription factor ATF4 ([@bib19]), which during translational inhibition is a transcriptional activator of GADD34 gene expression ([@bib39]). We thus investigated whether NTZ affected GADD34 expression. We treated A549 cells with increasing concentrations of NTZ for 4 h and measured GADD34 mRNA levels. NTZ strongly induced GADD34 mRNA synthesis in an NTZ concentration-dependent manner ([Figure 3](#fig3){ref-type="fig"}E). We note that maximal GADD34 transcription was detected between 4 and 8 h post-NTZ stimulation of A549 cells (not shown).

To investigate whether GADD34 participates in NTZ\'s inhibitory effect on VSV, we knocked down GADD34 in A549 cells using the CRISPR/dCas9-KRAB strategy described above (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} and [Figures S1](#mmc1){ref-type="supplementary-material"} and [3](#fig3){ref-type="fig"}B) and infected these GADD34-depleted A549 cells ([Figure 3](#fig3){ref-type="fig"}F, left panel) with the VSV-Luc reporter virus. GADD34 depletion resulted in a significant increase in VSV infection/growth ([Figure 3](#fig3){ref-type="fig"}F, right panel, 0 μM NTZ data point), similar to previously reported findings with VSV and GADD34^−/−^ mouse embryonic fibroblasts ([@bib42]). Furthermore, GADD34 depletion reduced VSV sensitivity to NTZ (50% inhibition at 4.8 μM NTZ in CRISPR-Ctrl A549 cells versus at 6.9 μM NTZ in GADD34-KD A549 cells) ([Figure 3](#fig3){ref-type="fig"}F, right panel), indicating that NTZ\'s anti-VSV activity also depends on its ability to induce the expression of GADD34 in addition to its enhancement of RIG-I function. Taken together, although RIG-I, PKR, and GADD34, play a role in host inhibition of VSV, only RIG-I and GADD34, and not PKR, are involved in NTZ-mediated repression of this virus.

NTZ Suppresses EBOV Replication through RIG-I and PKR {#sec2.4}
-----------------------------------------------------

We next analyzed EBOV replication in the CRISPR/dCas9-RIG-I-KD, PKR-KD, and GADD34-KD A549 cells under biosafety level 4 conditions to determine the individual roles of these antiviral proteins in restricting EBOV growth. Both RIG-I and PKR depletion led to significantly increased EBOV Kikwit replication ([Figure 4](#fig4){ref-type="fig"}A), with an increase of greater than a log unit by 72 h post-infection when compared with control cells ([Figure 4](#fig4){ref-type="fig"}A, right). This experiment demonstrates the importance of both factors in host control of EBOV infection. By contrast, although GADD34 depletion resulted in higher EBOV titers at 48 h, it did not impact EBOV growth by 72 h post-infection ([Figure 4](#fig4){ref-type="fig"}A, right). Thus, unlike what we found with VSV, GADD34 plays a limited role in restricting EBOV growth in A549 cells.Figure 4NTZ Requires PKR and RIG-I, but Not GADD34, for Full Inhibition of EBOV Replication in A549 Cells(A) Knockdown of RIG-I and PKR in A549 cells augments EBOV replication, whereas knockdown of GADD34 has a more modest effect on EBOV growth. Cells were mock-treated or treated with 20 μM NTZ for 4 h and infected with EBOV at MOI of 0.01 in the presence of pretreatment NTZ supernatants. Supernatants were harvested at 1, 48, or 72 h, clarified, and EBOV plaque-forming unit (PFU) was calculated by plaque assay. Titers are displayed on linear (left) and log (right) scales for clarity. \*\*p \< 0.01, \*\*\*p \< 0.001.(B) Compared with control A549 cells, NTZ inhibition of EBOV replication is impaired in RIG-I-KD and PKR-KD A549 cells but is not affected by GADD34 knockdown. Cells were mock-treated or treated with 20 μM NTZ for 4 h and infected with EBOV at MOI of 0.01 in the presence of pretreatment NTZ supernatants. Supernatants were harvested at 1, 48, or 72 h, clarified, and EBOV PFU was calculated by plaque assay. Titers are displayed on linear (left) and log (right) scales for clarity.

To determine if RIG-I, PKR, or GADD34 were targets of NTZ and required for its inhibitory effects upon EBOV, we next pretreated the CRISPR/dCas9-KRAB nonspecific control cells and the CRISPR/dCas9-RIG-I-KD, PKR-KD, or GADD34-KD A549 cell lines with 0 or 20 μM NTZ for 4 h and then infected with EBOV Kikwit at an MOI of 0.01. As shown in [Figure 4](#fig4){ref-type="fig"}B (left), there was a 10.5-fold reduction (\>1 log change) in NTZ\'s anti-EBOV activity in CRISPR/PKR-KD A549 cells by 72 h post-infection when compared with the CRISPR/Control A549 cells, indicating that PKR activity plays a critical role in NTZ\'s efficacy against EBOV. RIG-I depletion also resulted in an appreciable, although lesser, reduction in EBOV sensitivity to NTZ (2.7-fold) by 72 h post-infection ([Figure 4](#fig4){ref-type="fig"}B). By contrast, GADD34 depletion had little effect on NTZ\'s ability to inhibit EBOV growth ([Figure 4](#fig4){ref-type="fig"}B).

Discussion {#sec3}
==========

Here, we have shown that the FDA-approved small molecule drug NTZ broadly amplifies cytoplasmic RNA sensing and type I IFN pathways and strongly inhibits replication of EBOV and VSV. Our data indicate that NTZ\'s amplification of RIG-I and PKR activities overcomes EBOV VP35\'s ability to prevent the triggering of these critical host antiviral factors. By contrast, in the case of VSV, NTZ-mediated amplification of RIG-I signaling and induction of GADD34 expression, both contribute to the drug\'s anti-VSV activity. Thus, the wide array of innate immune activities that NTZ amplifies provides cells with the capacity to resist productive infection by diverse viruses like EBOV and VSV that engage distinct host evasion mechanisms.

VP35 blocks RIG-I-driven type I IFN production and PKR activation by both sequestering dsRNA intermediates and binding to the PKR/RIG-I activator PACT ([@bib4], [@bib8], [@bib21], [@bib34], [@bib38], [@bib59]). Furthermore, mutations in the dsRNA-binding pocket of EBOV VP35 were found to increase type I IFN induction *in vitro* and severely attenuate viral growth *in vivo* ([@bib27], [@bib49]). However, the relative importance of individual dsRNA-triggered cytoplasmic sensors for control of EBOV replication has not been clearly delineated. Our data here show that dCas9-KRAB-mediated knockdown of either RIG-I or PKR in A549 cells leads to a significant increase in EBOV replication (∼1 log) after 72 h, directly demonstrating that both these host molecules contribute to control of EBOV growth. The fact that a wild-type clinical EBOV isolate with an intact VP35 as part of its genome is still susceptible to the effects of RIG-I and PKR underscores the critical roles played by both these factors in host control of EBOV. Furthermore, our data showing that NTZ\'s efficacy against EBOV is reduced when host cell expression of either PKR or RIG-I is ablated, indicates that the ability of NTZ to increase the activity of PKR and RIG-I at an early stage of EBOV infection, can tip the balance in favor of the host by blunting VP35\'s ability to suppress the innate immune response.

NTZ also suppressed VSV replication, and its antiviral efficacy was markedly reduced upon depletion of RIG-I in A549 cells. However, unlike what we observed for EBOV, knockdown of PKR had no effect on NTZ inhibition of VSV. Furthermore, in the absence of NTZ, we found that knockdown of PKR resulted in a significant but milder increase in VSV growth relative to the robust increase in EBOV replication we observed when PKR expression was ablated. We note that the VSV matrix protein blocks host cell type I IFN responses independently of PKR by inhibiting global mRNA synthesis and nuclear export, as well as by inhibiting global host protein synthesis ([@bib2], [@bib7], [@bib14], [@bib22], [@bib33]). The VSV matrix protein shuts down host cell translation primarily by inducing dephosphorylation of the eIF4F initiation complex component eIF4E ([@bib13], [@bib14]). However, eIF2α also becomes phosphorylated at later stages of VSV infection, leading to additional negative effects on host protein synthesis, including on type I IFN production, as well as on viral protein synthesis ([@bib14]). Here, we have shown that NTZ induces transcription and translation of GADD34, which is a phosphatase that reverses eIF2α phosphorylation ([@bib43]), and has been shown to be critical for restoring translation of IFN-β and other selected cytokines in virus-infected cells ([@bib11], [@bib12], [@bib16]). Given that GADD34 depletion reduces NTZ activity against VSV, our data suggest that NTZ induction of GADD34 further amplifies NTZ-augmented RIG-I signaling, providing cells with the capacity to mount an innate immune response that is sufficient to overcome VSV matrix protein inhibitory effects upon protein synthesis.

Our data also show that the activities of factors downstream of the RLRs are amplified by NTZ. Both overexpressed MAVS and constitutively phosphorylated IRF3 activities were amplified in response to NTZ stimulation, resulting in increased type I IFN promoter activity. NTZ also enhanced type I IFN-induced mRNA synthesis of ISGs Mx1, IFI27, and IFITM3. IFITM3 is a critical restriction factor for both EBOV ([@bib28]) and VSV ([@bib28], [@bib67]), and Mx1 has been shown to inhibit VSV infection ([@bib63]). Thus, NTZ\'s ability to amplify both proximal and distal aspects of the viral RNA sensing and type I IFN pathways allows for a broad and effective antiviral response to develop in cells that are immediate viral targets and in neighboring cells yet to be infected.

Although three previous reports have suggested that ISGs induced by NTZ or its metabolite TIZ play an antiviral role, a direct functional impact of NTZ or TIZ upon any of these genes with respect to inhibition of viral growth, has not been shown. For example, one report described increased average expression of a panel of 26 ISGs in peripheral blood mononuclear cells (PBMCs) treated with a very low concentration (0.1 μM) of NTZ for an unspecified time, with no functional demonstration of how any of these individual ISGs affected replication of a virus in NTZ-treated cells ([@bib45]). Another article reported that treatment of human monocyte-derived macrophages (MDM) with NTZ for 48 h induced the expression of the ISGs tetherin and APOBEC3A/G, and although the authors associated this with NTZ inhibition of HIV in MDMs, no functional demonstration was provided showing that these molecules played any role in NTZ\'s anti-HIV activity ([@bib25]). A third study reported that TIZ treatment of human PBMCs for 7 days induced a set of 14 IFNs and ISGs approximately 2-fold when compared with untreated PBMCs, with a slightly greater increase, on average, observed in the context of HIV infection (including Mx1, 1.8- to 2.9-fold respectively); however, again, no functional links between the ISGs identified and NTZ inhibition of HIV replication were made, and no mechanism for this response was investigated ([@bib65]). In contrast to the above studies, through both biochemical and gene knockdown approaches we have demonstrated that NTZ treatment results in broad amplification of RLR pathway components that are primary drivers of type I IFN production and ISG induction and amplifies type I IFN signaling. Furthermore, we have functionally linked RIG-I and PKR to NTZ\'s antiviral activity against EBOV, and functionally linked RIG-I and GADD34 to NTZ\'s activity against VSV using CRISPR/dCas9-KRAB-mediated knockdown of these molecules in host cells.

It has also been previously reported that NTZ induces phosphorylation of PKR in different cell lines. However, weak NTZ-induced PKR phosphorylation was only observed in one study after 72 h of 0.5 or 5 μM NTZ exposure in human hepatoma cells harboring an hepatitis C virus (HCV) replicon ([@bib19]), and after 24 h in a bovine kidney cell line with 25 μM, but not 10 μM, NTZ in another study ([@bib3]). Furthermore, in both reports, no direct functional link between putative PKR phosphorylation by NTZ and its antiviral activity was demonstrated, thus leaving unverified the functional importance of PKR, or its phosphorylation status, for NTZ\'s ability to suppress replication of PKR-sensitive viruses. By contrast, our demonstration that the effect of NTZ on EBOV growth is markedly impaired in cells where PKR expression has been ablated directly links NTZ pretreatment for 4 h before EBOV infection to PKR restriction of EBOV growth.

Synthetic RLR agonists for the treatment of viruses have generated much interest ([@bib71]). However, because RLRs are expressed in most human tissues and the inflammatory response to their induction is highly variable person to person, there is concern that therapeutic approaches employing RNA agonists will be associated with unacceptable inflammatory side effects ([@bib20]). Intriguingly, NTZ has been used extensively with an excellent safety profile in adults and children for treatment of parasitic infections ([@bib18], [@bib29], [@bib53]), and for viral diseases such as HCV ([@bib55], [@bib56]) and influenza ([@bib26]). Notably, our findings indicate that NTZ modulate the innate immune response after a pathogen has entered a susceptible target cell, when amplification of natural immune control of viral infection is needed. In the case of viruses like EBOV that employ immune evasion mechanisms to avoid triggering the innate immune response, such a therapeutic profile is attractive. Although identification of NTZ\'s upstream target is outside the scope of this article, we anticipate that these studies, which are underway, will be of great value in unraveling host pathways that lead to cell-intrinsic control of Ebola.

Finally, the studies presented here suggest that after validation in an *in vivo* animal model, NTZ could be potentially useful in EBOV disease as monotherapy or as an adjuvant therapy with agents that specifically target EBOV components. Furthermore, NTZ may also prove valuable in strategies to prevent EBOV infection or to eradicate EBOV reservoirs that persist in patients who have survived EBOV disease.

Limitations of the Study {#sec3.1}
------------------------

Although NTZ is FDA approved for the treatment of cryptosporidial diarrhea and is a well-tolerated medication, a limitation of the data presented here regarding NTZ\'s inhibition of EBOV is that it is based on *in vitro* studies and we have not yet established NTZ\'s efficacy against EBOV in an *in vivo* animal model. Furthermore, the detailed investigation of NTZ\'s upstream target in the regulation of the immune responses described here is outside the scope of this article and will be the subject of future studies, as will *in vivo* testing of NTZ against EBOV.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figure S1
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